Business Context and Reporting Period
This Form 8-K Current Report was filed by Community Health Systems, Inc. on February 17, 2023, regarding events occurring on February 15, 2023. The filing details the Board of Directors' approval of 2023 compensation arrangements for the Company's Named Executive Officers (NEOs), including base salaries, cash incentive targets, and long-term equity awards.
Key Financial Metrics and Compensation Details
The filing does not report operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. Instead, it discloses specific compensation figures for fiscal year 2023:
- CEO Base Salary: Tim L. Hingtgen approved at $1,287,500.
- Cash Incentive Targets: CEO target opportunity set at 225% of base salary; CFO at 125%; President of Clinical Operations at 115%; Regional President at 100%.
- Equity Grants (Effective March 1, 2023):
- CEO: 200,000 Stock Options, 200,000 Time-Vesting Restricted Stock, 400,000 Performance-Based Restricted Stock.
- CFO: 90,000 Stock Options, 90,000 Time-Vesting Restricted Stock, 180,000 Performance-Based Restricted Stock.
- President of Clinical Operations: 40,000 Stock Options, 40,000 Time-Vesting Restricted Stock, 80,000 Performance-Based Restricted Stock.
- Regional President: 25,000 Stock Options, 25,000 Time-Vesting Restricted Stock, 50,000 Performance-Based Restricted Stock.
- Director Compensation Adjustment: A $265,000 annual cash stipend for former Executive Chairman Wayne T. Smith was converted to a grant of time-based Restricted Stock Units (RSUs) with a fair value of approximately $265,000.
Material Changes Versus Prior Period
The filing does not provide comparative financial data or explicit percentage changes in compensation versus the prior year. However, it notes the following structural changes:
- Mark B. Medley is expected to be included as a Named Executive Officer in the 2023 proxy statement, whereas he was not previously listed in that capacity.
- Wayne T. Smith and Benjamin C. Fordham are excluded from the 2023 NEO compensation plan due to Smith's transition to non-executive Chairman and Fordham's retirement.
- Performance-based restricted stock awards are subject to a three-year performance period (2023–2025) with vesting ranging from 0% to 200% of the target grant.
Guidance, Outlook, and Risks
The filing contains no financial guidance, revenue outlook, or discussion of market risks. The primary contingencies relate to executive compensation:
- Performance Contingency: Cash incentives and performance-based restricted stock are contingent upon achieving specific financial and non-financial performance goals. Non-financial improvements can add up to 40% (CEO), 35% (CFO), or 10% (CMO) to base salary targets.
- Overachievement: Additional cash incentives are available for overachievement of goals, capped at 35% for the CEO and 25% for other NEOs.
- Vesting Schedule: Equity awards vest ratably over three years, beginning on the first anniversary of the grant date.
Important Facts for Investor Verification
- Verify the specific performance metrics tied to the 0–200% vesting range for performance-based restricted stock in the definitive proxy statement.
- Confirm the total dilution impact of the 1,000,000+ shares of equity granted to NEOs in the 2023 fiscal year.
- Review the definitive proxy statement for the 2023 annual meeting to see actual payouts for 2022 incentive targets.
- Monitor the conversion of Wayne T. Smith's cash stipend to RSUs and its impact on director compensation disclosures.